海和CYH33跻身儿童抗肿瘤药星光计划，小分子研发硬实力正在被看见

Group 1 - The core point of the news is that Shanghai Haihe Pharmaceutical has been included in the "Star Plan" for the development of pediatric anti-tumor drugs, highlighting its strength in small molecule innovative drug research and development [1][2] - CYH33, a selective PI3Kα inhibitor, targets rare diseases such as PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformations (PRVM), addressing a significant treatment gap for patients [2] - The inclusion of CYH33 in the Star Plan reflects the company's long-term commitment to small molecule innovative drug development, following previous successes with other innovative drugs [2][3] Group 2 - Haihe Pharmaceutical is advancing its value in the market through a comprehensive approach that includes research, clinical trials, commercialization, and internationalization [3] - The innovative drug industry is undergoing structural adjustments, and companies with core technologies and clear clinical value are better positioned to succeed in a competitive environment [3] - The ongoing clinical trials, expansion into overseas markets, and the launch of more pipeline products are expected to drive growth for Haihe Pharmaceutical and contribute to the overall value increase for the Huayi family [3]